Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis.
August 6, 2026 11:33 AM EDTUpdated 11:51 AM
Intellia says it has found a key clue to its gene editing safety issues
Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a…
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory…
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now…
